Want to see GTBP full AI Analyst Report?
GTBP Stock Chart & Stats
$0.32
-$0.01(-3.25%)
At close: 4:00 PM EDT
$0.32
-$0.01(-3.25%)
Day’s Range― - ―
52-Week Range$0.26 - $1.37
Previous CloseN/A
Volume415.79K
Average Volume (3M)1.63M
Market Cap
$12.42M
Enterprise Value$13.96
Total Cash (Recent Filing)$4.96M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Nov 11, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.16
Shares Outstanding45,109,497
10 Day Avg. Volume1,818,785
30 Day Avg. Volume1,629,462
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.75
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside837.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Zero DebtThe absence of debt limits interest and refinancing pressure, preserving flexibility for research and clinical development. This is an important structural strength for a pre-revenue biotechnology company, although it does not offset the need for additional operating funding.
Immuno-Oncology PlatformThe company is focused on a specialized immuno-oncology platform intended to direct and activate immune cells against tumors. If development succeeds, this approach could support multiple cancer indications and create broader pipeline leverage than a single-asset strategy.
Capital Structure FlexibilityThe approved capital-structure flexibility may help management address exchange-listing requirements and simplify future financing actions. That can support business continuity over the next several months, although any financing benefit depends on execution and investor support.
Bears Say
No Commercial RevenueGT Biopharma remains pre-commercial, so it lacks product revenue to fund operations or validate commercial demand. Continued losses leave financial performance dependent on clinical progress, partnerships, or external capital rather than an established operating model.
Accelerating Cash BurnPersistent and worsening cash outflows indicate that research and clinical activities consume substantial funds without internally generated cash support. This raises the likelihood of additional financing and makes development continuity sensitive to capital-market access.
Thin, Shrinking Balance SheetThe reduced asset base and volatile equity cushion weaken financial resilience, even with zero debt. Limited resources may constrain the pace of pipeline development and reduce the company’s ability to absorb trial setbacks or prolonged funding delays.
GT Biopharma News
GTBP FAQ
What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest stock price was $0.26 and its highest was $1.37 in the past 12 months.
What is GT Biopharma’s market cap?
GT Biopharma’s market cap is $12.42M.
When is GT Biopharma’s upcoming earnings report date?
GT Biopharma’s upcoming earnings report date is Nov 11, 2026 which is in 82 days.
How were GT Biopharma’s earnings last quarter?
GT Biopharma released its earnings results on Aug 14, 2026. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.08 by -$0.04.
Is GT Biopharma overvalued?
According to Wall Street analysts GT Biopharma’s price is currently Undervalued.
Does GT Biopharma pay dividends?
GT Biopharma does not currently pay dividends.
What is GT Biopharma’s EPS estimate?
GT Biopharma’s EPS estimate is -0.1.
How many shares outstanding does GT Biopharma have?
GT Biopharma has 45,109,497 shares outstanding.
What happened to GT Biopharma’s price movement after its last earnings report?
GT Biopharma reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.08. Following the earnings report the stock price went down -0.337%.
Which hedge fund is a major shareholder of GT Biopharma?
Currently, no hedge funds are holding shares in GTBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GT Biopharma
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
GTBP Stock 12 Month Forecast
Average Price Target
$3.00
▲(837.50% Upside)
Technical Analysis
Theriva Biologics
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Azitra Inc
―
Ownership Overview
1.90%
Insiders
1.06% Mutual Funds
1.42% Other Institutional Investors
94.78% Public Companies and
Individual Investors